RITUXAN: A LEGACY OF EXPERIENCE

  • Rituxan + MTX has more than a decade of clinical experience in RA[11]
  • Rituxan + GCC is the only FDA-approved induction treatment for adult patients with GPA and MPA[11]

Rituxan Milestones

CYC, cyclophosphamide; GCC, glucocorticoids; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MTX, methotrexate; PV, pemphigus vulgaris; RA, rheumatoid arthritis; TNFi, tumor necrosis factor inhibitor; TNF-IR, tumor necrosis factor inhibitor–inadequate responder.

INDICATIONS

  • Rituxan® (rituximab), in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more TNF antagonist therapies
  • Rituxan® (rituximab), in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)
  • Rituxan® (rituximab) is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris